1. Home
  2. WY vs STTK Comparison

WY vs STTK Comparison

Compare WY & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weyerhaeuser Company

WY

Weyerhaeuser Company

HOLD

Current Price

$26.73

Market Cap

17.2B

Sector

Real Estate

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.91

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WY
STTK
Founded
1900
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2B
275.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WY
STTK
Price
$26.73
$3.91
Analyst Decision
Buy
Buy
Analyst Count
7
7
Target Price
$28.71
$6.20
AVG Volume (30 Days)
7.9M
683.9K
Earning Date
01-29-2026
03-26-2026
Dividend Yield
3.11%
N/A
EPS Growth
N/A
N/A
EPS
0.45
N/A
Revenue
$6,905,000,000.00
$1,000,000.00
Revenue This Year
$5.49
N/A
Revenue Next Year
$8.69
N/A
P/E Ratio
$60.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.16
$0.69
52 Week High
$31.66
$4.89

Technical Indicators

Market Signals
Indicator
WY
STTK
Relative Strength Index (RSI) 69.97 51.62
Support Level $26.37 $3.76
Resistance Level $27.75 $4.23
Average True Range (ATR) 0.74 0.30
MACD -0.02 -0.04
Stochastic Oscillator 87.09 51.06

Price Performance

Historical Comparison
WY
STTK

About WY Weyerhaeuser Company

Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: